July 26, 2024 — Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Dasynoc, a novel treatment for chronic…Original Article
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
